Evidence map›Paper›PMID 41559399›Full record

ArticleNPJ precision oncology2026

Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy.

Gaurav Sharma, Yasmine Baca, Sanjay Goel, Anthony F Shields, Ajay Prakash, Benjamin A Weinberg, Anwaar Saeed, Chadi Nabhan, Matthew Oberley, Joanne Xiu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gaurav SharmaDivision of Hematology and Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Yasmine BacaCARIS Life Sciences, Phoenix, AZ, USA.
Sanjay GoelRutgers Cancer Institute, New Brunswick, NJ, USA.
Anthony F ShieldsBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
Ajay PrakashDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Benjamin A WeinbergLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Anwaar SaeedUniversity of Pittsburgh, Pittsburgh, PA, USA.
Chadi NabhanCARIS Life Sciences, Phoenix, AZ, USA.
Matthew OberleyCARIS Life Sciences, Phoenix, AZ, USA.
Joanne XiuCARIS Life Sciences, Phoenix, AZ, USA.
Justin HwangDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Emmanuel S AntonarakisDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Vi K ChiuThe Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA.
Emil LouDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA. Emil-lou@umn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are utilized to treat hepatocellular carcinomas (HCC) without validated biomarkers. We sought to identify genomic signatures and immune patterns predicting treatment efficacy in 1,306 HCC patients to evaluate for potential predictive biomarkers associated with immunotherapy outcome. Programmed death ligand 1 (PD-L1) expression was high in 6.1% and low in 11.6%; deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) was detected in only 0.2%, and high tumor mutational burden (TMB-H) in 5.1% of the patients. Immuno-oncologic (IO) markers (CD80, HAVCR2, PDCD1, IFNG, CTLA4, IDO1, CD86, LAG3, PDCD1LG2) correlated with PD-L1 expression (q < 0.05). Infiltration of B cells, M1 macrophages, CD8 + T cells, and T

Identifiers

PMID41559399
PMCPMC12948995

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.